Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society

Zynerba Pharmaceuticals

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) has announced the acceptance and presentation details of two posters at the 2020 virtual annual meeting of the American Epilepsy Society (AES). The AES annual meeting is being held virtually from December 4th through December 8th, 2020.

A copy of the posters will be made available on the Zynerba corporate website at the time of presentation at http://zynerba.com/publications/.

Title: ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Open‐label Clinical Trial [BELIEVE (ZYN2-CL-25)] Abstract #: 913882
Poster #: 983
Presentation Date: December 4, 2020

Title: Quality of Life and Caregiver Qualitative Assessments in Children with Developmental and Epileptic Encephalopathies Treated with ZYN002 (CBD) Transdermal Gel: BELIEVE (ZYN2-CL-025)
Abstract #: 913851
Poster #: 984
Presentation Date: December 4, 2020

READ:  Endo Aesthetics Launches "Really Cellulite" Campaign

Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee